OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

Second Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid and liquid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan, Sept. 19, 2018 -- (Healthcare Sales & Marketing Network) -- OBI Pharma... Biopharmaceuticals, Oncology, FDA OBI Pharma, Acute Lymphoblastic Leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news